Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our high-tech, dedicated method is applied to construct targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q6ZMP0

UPID:
THSD4_HUMAN

ALTERNATIVE NAMES:
A disintegrin and metalloproteinase with thrombospondin motifs-like protein 6

ALTERNATIVE UPACC:
Q6ZMP0; B2RTY3; B4DR13; Q6MZI3; Q6UXZ8; Q9H8E4

BACKGROUND:
The protein Thrombospondin type-1 domain-containing protein 4, with its alternative name a disintegrin and metalloproteinase with thrombospondin motifs-like protein 6, is instrumental in the assembly of the FBN1 matrix and the attenuation of TGFB signaling. This action is crucial for the negative regulation of TGFB regulatory targets, including POSTN, highlighting its role in cellular processes.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of Thrombospondin type-1 domain-containing protein 4 could open doors to potential therapeutic strategies for managing Aortic aneurysm, familial thoracic 12. This disease's association with the protein suggests that interventions targeting its function may offer new avenues for treatment, emphasizing the therapeutic significance of this protein.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.